Overview

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Novartis
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Trametinib